Campaigners, advocates and some politicians are calling on the Government and the HSE to reimburse Skyclarys, a medicine for Friedreich’s ataxia (FA), after a Drugs Group decision not to cover the treatment. People affected by the rare disease and their supporters describe the drug as life-changing and say lack of reimbursement leaves patients without access.
According to reports, the HSE Drugs Group recommends against public coverage of Skyclarys, prompting public pressure. The Irish Independent focuses on the campaign and the efforts by advocates and politicians to secure reimbursement, including accounts of how the condition affects patients’ lives. BreakingNews.ie highlights the underlying decision by the HSE Drugs Group as the trigger for patients’ appeals, framing it as a plea for access to the therapy.
While outlets differ in emphasis—some foreground patient advocacy and political lobbying, others foreground the HSE recommendation itself—they describe the same dispute: whether Skyclarys should be funded for people living with Friedreich’s ataxia.
